Mycovia Pharmaceuticals, Inc.


Mycovia Pharmaceuticals is dedicated to making a difference in patients' lives by advancing treatments for under-addressed medical conditions, with a focus on women's health and overlooked diseases. They develop innovative therapies through science, collaborate with partners, and are committed to treatment equality and community impact.

Industries

health-care
pharmaceutical

Nr. of Employees

small (1-50)

Mycovia Pharmaceuticals, Inc.

Durham, North Carolina, United States, North America


Products

Oral oteseconazole capsules (150 mg)

Oral small-molecule antifungal therapy formulated as 150 mg capsules indicated for treatment of severe vulvovaginal candidiasis (as described on product pages and prescribing information).


Services

Investigator-initiated study support

Program to accept and review independent investigator study concepts, supply request forms, and offer limited, non-design-influencing support.

Medical information and adverse event reporting

Telephone and email-based medical information service and designated channel for adverse event and product complaint reporting.

Partnerships, licensing and commercialization support

Negotiation and management of licensing agreements and commercialization collaborations with regional partners.

Expertise Areas

  • Antifungal drug development
  • Clinical trial design and management
  • Clinical pharmacology and safety assessment
  • Pharmacovigilance and medical information
  • Show More (3)

Key Technologies

  • Small-molecule antifungal drug development
  • Clinical trial management and registry reporting
  • Clinical pharmacology assessments (PK/PD; renal/hepatic impairment; QT interval)
  • Pharmacovigilance and adverse event reporting systems
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.